12:00 AM
 | 
Apr 10, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 4/7 cls
Altus (ALTU) SG Cowen Eric Schmidt New NA -1% $21.76
Schmidt believes that lead product ALTU-135, which has completed a Phase II trial for pancreatic insufficiency, could receive FDA approval in 2008.
Anadys (ANDS) ThinkEquity Andrew McDonald New Accumulate -13% $13.94
McDonald set a $16 target. He believes ANA975 has the potential to replace the interferon component in HCV treatment regimens. The prodrug of isatoribine, a toll like receptor 7 (TLR7) agonist, is in Phase I testing.
Bavarian Nordic (CSE:BAVA) Danske Bank Carsten Lonborg Upgrade Buy (from hold) 12% DKK506
Lonborg said a $38.8M private placement late...

Read the full 725 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >